|
Reteplase
resources
|
|
|
|
|
|
DRUG INFO
Reteplase
Drug Name:
Reteplase
Indication: For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction
Pharmacology: Retavase cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.
Mechanism Of Action: Retavase cleaves the Arg/Val bond in plasminogen to form plasmin. This in turn leads to the degradation of blood clots.
Drug Category: Thrombolytic Agents
Brand Names/Synonyms: Tissue-type plasminogen activator precursor;tPA;t- PA;t-plasminogen activator;Alteplase;Reteplase; Retavase (Centocor); Retavase (Roche)
Dosage Forms: LIQUID;POWDER FOR SOLUTION
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Human tissue plasminogen activator fragment
Chemical Formula: C1736H2671N499O522S22
Half Life: Not Available
Drug Type: Approved Drug
# Accession No: BIOD00013
CAS Registry Number: 133652-38-7
|
|
|
|
|
|
Reteplase News
(When available)
Protein Design Labs Becomes PDL BioPharma Jan 9, 2006
MSN Money Cardene(R) IV (nicardipine hydrochloride) for short-term treatment of hypertension when oral therapy is not feasible or desirable, Retavase(R) (reteplase) for ...
|
|
|
